Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Download
[thumbnail of PIIS0140673622020839.pdf]
Preview
PIIS0140673622020839.pdf - Published Version (617kB) | Preview
Available under license: Creative Commons Attribution
Export

Kalra, Paul R, Cleland, John GF, Petrie, Mark C, Thomson, Elizabeth A, Kalra, Philip A, Squire, Iain B, Ahmed, Fozia Z, Al-Mohammad, Abdallah, Cowburn, Peter J, Foley, Paul WX, Graham, Fraser J, Japp, Alan G, Lane, Rebecca ORCID: 0000-0002-8658-2739, Lang, Ninian N, Ludman, Andrew J, Macdougall, Iain C, Pellicori, Pierpaolo, Ray, Robin, Robertson, Michele, Seed, Alison and Ford, Ian (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet, 400 (10369). pp. 2199-2209. ISSN 0140-6736

Dimensions Badge

Altmetric Badge

Item type Article
URI https://vuir.vu.edu.au/id/eprint/47405
DOI 10.1016/S0140-6736(22)02083-9
Official URL https://www.sciencedirect.com/science/article/pii/...
Subjects Current > FOR (2020) Classification > 4203 Health services and systems
Current > Division/Research > Institute for Health and Sport
Keywords iron repletion; iron therapy; hospital admissions; cardiovascular death; ferric carboxymaltose; quality of life
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login

CORE (COnnecting REpositories)